
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific's stock outlook is supported by impressive year-over-year growth in several key segments, including a 35% increase in Watchman sales and a remarkable 63% growth in its electrophysiology (EP) division, reflecting strong market demand and share gains. The company projects organic sales growth of 11-13% for Q4, alongside expected revenues of approximately $5.222 billion to $5.314 billion, showcasing robust overall growth momentum. Additionally, Boston Scientific's innovative product lines, such as the Nalu device anticipated to generate over $60 million in sales by 2025, further underscore the firm's potential for sustained financial performance and market expansion.
Bears say
Boston Scientific's outlook appears negative due to anticipated foreign exchange headwinds of approximately $0.04 per adjusted share, coupled with slight reductions in future revenue forecasts stemming from quarterly performance misses. The company faces significant challenges in its Cardiac Rhythm Management (CRM) and Drug-Eluting Stent (DES) portfolios, which operate in mature markets enduring persistent pricing pressure. Additionally, any setbacks in new product launches or difficulties in integrating acquisitions could further hinder Boston Scientific's growth potential, as reflected in missed performance expectations in various segments, including a notable shortfall in the Urology sector.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares